Information in the news releases is current on the date of the announcement, but is subject to change without prior notice. |
| 2006 Release |
 |
| November 21, 2006 |
|
Eisai Announces Establishment of New Pharmaceuticals Marketing Subsidiary in Portugal
|
|
| November 20, 2006 |
|
Eisai Recieves Positive Opinion for Inovelon Marketing Authorization from European Committee for Medicinal Products for Human Use (CHMP)
|
|
| October 31, 2006 |
|
Eisai Launches New Rx-to-OTC Switch Product Higuard for Allergy-related Rhinitis and Skin Problems
|
|
| October 30, 2006 |
|
Notice Regarding Revision of the Annual Business Forecast and Year-end Dividend Forecast by Subsidiary
|
|
| October 26, 2006 |
|
Eisai Announces Completion of Acquisition of Four Oncology-Related Products from Ligand
|
|
| October 19, 2006 |
|
Sanko Junyaku, Eisai, and FUJIREBIO Sign Joint Research Agreement for Development of a New KL-6 Test Kit (supplementary diagnostic marker for interstitial pneumonia) compatible with LUMIPULSE (automatic chemiluminescent enzyme immunoassay system)
|
|
| October 19, 2006 |
|
Notice Regarding Revision of the Semiannual Business Forecast by Subsidiary
|
|
| October 14, 2006 |
|
U.S. FDA Approves Aricept For Treatment of Severe Alzheimer's Disease
|
|
| October 9, 2006 |
|
Eisai Receives Decisions of Summary Judgment Motion in US Legal Action Over Aciphex ANDA Filing
|
|
| October 2, 2006 |
|
Eisai's research subsidiary “KAN Research Institute” launches research operations in The Kobe Medical Industry Development Project Site
|
|
| September 27, 2006 |
|
Eisai's Lawsuit against three Japanese Generic drug manufacturers/distributors regarding the sales of Selbex based on the Japanese Unfair Competition Prevention Law dismissed by Court
|
|
| September 8, 2006 |
|
Eisai Acquires Four Oncology-Related Products from Ligand
|
|
| August 30, 2006 |
|
Notice Concerning the Result of the Company's Own Share Acquisition through ToSTNet-2
|
|
| August 29, 2006 |
|
Notice Concerning Acquisition of the Company's Own Shares through ToSTNet-2
|
|
| August 4, 2006 |
|
Eisai Commences U.S. Legal Action over Aricept ODT ANDA Filing
|
|
| July 31, 2006 |
|
Eisai Starts Marketing Severe Chronic Pain Agent Prialt in the UK and Germany
|
|
| July 31, 2006 |
|
Continuation of Policy for Protection of the Company's Corporate Value and Common Interests of Shareholders
|
|
| July 31, 2006 |
|
Notice Concerning Acquisition of the Company's Own Shares
|
|
| July 27, 2006 |
|
Co-development and Distribution Agreement on treatment for pancreatic exocrine insufficiency (SA-001) in Japan concluded
|
|
| July 12, 2006 |
|
Eisai and Teva Mutually Agree To End Collaboration Agreement for Rasagiline
|
|
| July 10, 2006 |
|
Notice on Stock Options (New Share Subscription Rights) Including the Amount Paid In Upon the Exercise of Stock Options
|
|
| July 4, 2006 |
|
Pharmaceutical Marketing Subsidiary in Singapore Launches Operations
|
|
| June 29, 2006 |
|
Eisai Licenses Selective Estrogen Receptor Modulators (SERMs) to Radius
|
|
| June 23, 2006 |
|
Notice on Allotment of Stock Options (New Share Subscription Rights)
|
|
| May 19, 2006 |
|
Notice Concerning Dissolution of Subsidiary
|
|
| May 16, 2006 |
|
Notice on Partial Amendments to the Articles of Incorporation
|
|
| May 16, 2006 |
|
Notice on New Stock Issuance in the Form of Stock Options
|
|
| May 16, 2006 |
|
Eisai Files Application with the MHRA for New Aricept Indication: Severe Alzheimer's Disease
|
|
| May 10, 2006 |
|
Eisai and Nitto Denko Sign a Joint Development Agreement on a Transdermal Patch Formulation of Aricept
|
|
| May 9, 2006 |
|
Eisai will initiate first clinical study for E2012, a potential new treatment for Alzheimer's Disease
|
|
| April 21, 2006 |
|
Personal Information Documentation Loss Release
|
|
| April 17, 2006 |
|
Dainippon Sumitomo Pharma and Eisai Signed Licensing Agreement for "Gasmotin", a Gastroprokinetic Agent, for Countries in Asia including ASEAN Members
|
|
| March 31, 2006 |
|
Asahi Kasei Pharma and Eisai sign sales promotion agreement for Eril in China
|
|
| March 30, 2006 |
|
Eisai and DNAVEC Sign an Agreement on Drug Discovery Research for Vaccine Therapy for Alzheimer's Disease
|
|
| March 29, 2006 |
|
Notice of Shelf Registration for Stock Options
|
|
| March 27, 2006 |
|
Eisai Applies for a New Indication of Non-Erosive Gastro-Esophageal Reflux Disease for Pariet a Proton Pump Inhibitor, in Japan
|
|
| March 16, 2006 |
|
Eisai Reports Results from Latest Donepezil Study in Vascular Dementia
|
|
| February 28, 2006 |
|
Policy for Protection of the Company's Corporate Value and Common Interests of Shareholders
|
|
| February 28, 2006 |
|
Announcement of the 5th Mid-term Strategic Plan
|
|
| February 24, 2006 |
|
Notice Concerning the Split-off of Management Function of the R&D Division and Other Relevant Function of Eisai Co., Ltd.
|
|
| February 14, 2006 |
|
FDA Accepts Eisai's sNDA Application for Aricept In the Treatment of Severe Alzheimer's Disease
|
|
| February 9, 2006 |
|
Eisai Agrees To Acquire Severe Chronic Pain Agent Prialt For Europe From Elan
|
|
| February 2, 2006 |
|
Notice Concerning Revision of Year End Dividend Forecast For Fiscal Year Period (94th Company Fiscal Period) Ending March 2006
|
|
| January 24, 2006 |
|
Eisai establishes a European strategic business hub in the U.K.
|
|
| January 13, 2006 |
|
Legal Action taken against Generic Products of Eisai's Selbex Capsule 50mg based on the Japanese Unfair Competition Prevention Law in the Japanese Market
|
|
| | | |
